Omalizumab for management of hypersensitivity reactions to anticancer drugs

被引：0
作者：
Grover, Piyush [1 ,2 ,3 ]
Krummenacher, Matthew [1 ]
Loy, Timothy [1 ]
Nowak, Anna K. [2 ]
Lucas, Michaela [1 ,2 ,4 ,5 ]
机构：
[1] Sir Charles Gairdner Hosp, Dept Immunol, Perth, WA, Australia
[2] Univ Western Australia, Med Sch, Perth, WA, Australia
[3] Fiona Stanley Hosp, Dept Med Oncol, Perth, WA, Australia
[4] Perth Childrens Hosp, Dept Immunol, Perth, WA, Australia
[5] PathWest, Perth, WA, Australia
来源：
INTERNAL MEDICINE JOURNAL | 2024年 / 54卷 / 08期
关键词：
allergy; cancer drugs; omalizumab; desensitisation; DESENSITIZATION; IGE; ASTHMA;
D O I：
10.1111/imj.16464
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Hypersensitivity reactions to anticancer drugs include treatment-limiting toxicity. Standard drug desensitisation offers temporary tolerance and hence requires repetition. We used omalizumab, an anti-immunoglobulin E antibody, to overcome immediate and delayed hypersensitivity reactions to various anticancer drugs. Seven of the eight patients in the current study successfully resumed the desired anticancer drug regimen without standard desensitisation. No safety issues from omalizumab were observed.
引用
收藏
页码：1396 / 1400
页数：5
相关论文
共 21 条
  • [1] 5 CTCAE, US DEP HLTH HUMAN SE
  • [2] Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps
    Bagnasco, Diego
    Canevari, Rikki Frank
    Del Giacco, Stefano
    Ferrucci, Silvia
    Pigatto, Paolo
    Castelnuovo, Paolo
    Marseglia, Gian Luigi
    Yalcin, Arzu Didem
    Pelaia, Girolamo
    Canonica, Giorgio Walter
    [J]. WORLD ALLERGY ORGANIZATION JOURNAL, 2022, 15 (12):
  • [3] Does Rapid Drug Desensitization to Chemotherapy Affect Survival Outcomes?
    Berges-Gimeno, M. P.
    Carpio-Escalona, L., V
    Longo-Munoz, F.
    Bernal-Rubio, L.
    Lopez-Gonzalez, P.
    Gehlhaar, P.
    Pachon, V
    Ferreiro-Monteagudo, R.
    Madrigal-Burgaleta, R.
    Alvarez-Cuesta, E.
    [J]. JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 2020, 30 (04) : 254 - 263
  • [4] Successful treatment of idiopathic mast cell activation syndrome with low-dose Omalizumab
    Berry, Renee
    Hollingsworth, Peter
    Lucas, Michaela
    [J]. CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2019, 8 (10)
  • [5] Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs
    Broyles, Ana Dioun
    Banerji, Aleena
    Barmettler, Sara
    Biggs, Catherine M.
    Blumenthal, Kimberly
    Brennan, Patrick J.
    Breslow, Rebecca G.
    Brockow, Knut
    Buchheit, Kathleen M.
    Cahill, Katherine N.
    Cernadas, Josefina
    Chiriac, Anca Mirela
    Crestani, Elena
    Demoly, Pascal
    Dewachter, Pascale
    Dilley, Meredith
    Farmer, Jocelyn R.
    Foer, Dinah
    Fried, Ari J.
    Garon, Sarah L.
    Giannetti, Matthew P.
    Hepner, David L.
    Hong, David I.
    Hsu, Joyce T.
    Kothari, Parul H.
    Kyin, Timothy
    Lax, Timothy
    Lee, Min Jung
    Lee-Sarwar, Kathleen
    Liu, Anne
    Logsdon, Stephanie
    Louisias, Margee
    MacGinnitie, Andrew
    Maciag, Michelle
    Minnicozzi, Samantha
    Norton, Allison E.
    Otani, Iris M.
    Park, Miguel
    Patil, Sarita
    Phillips, Elizabeth J.
    Picard, Matthieu
    Platt, Craig D.
    Rachid, Rima
    Rodriguez, Tito
    Romano, Antonino
    Stone, Cosby A., Jr.
    Torres, Maria Jose
    Verdu, Miriam
    Wang, Alberta L.
    Wickner, Paige
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2020, 8 (09) : S16 - S116
  • [6] Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children
    Busse, William W.
    Morgan, Wayne J.
    Gergen, Peter J.
    Mitchell, Herman E.
    Gern, James E.
    Liu, Andrew H.
    Gruchalla, Rebecca S.
    Kattan, Meyer
    Teach, Stephen J.
    Pongracic, Jacqueline A.
    Chmiel, James F.
    Steinbach, Suzanne F.
    Calatroni, Agustin
    Togias, Alkis
    Thompson, Katherine M.
    Szefler, Stanley J.
    Sorkness, Christine A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (11) : 1005 - 1015
  • [7] Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 cases
    Castells, Mariana C.
    Tennant, Nichole M.
    Sloane, David E.
    Hsu, F. Ida
    Barrett, Nora A.
    Hong, David I.
    Laidlaw, Tanya M.
    Legere, Henry J.
    Nallamshetty, Samridhi N.
    Palis, Ross I.
    Rao, Jayanti J.
    Berlin, Suzanne T.
    Campos, Susana M.
    Matulonis, Ursula A.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2008, 122 (03) : 574 - 580
  • [8] Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features
    Ellis, Samantha R.
    Vierra, Aren T.
    Millsop, Jillian W.
    Lacouture, Mario E.
    Kiuru, Maija
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (04) : 1130 - 1143
  • [9] IgE and mast cells in allergic disease
    Galli, Stephen J.
    Tsai, Mindy
    [J]. NATURE MEDICINE, 2012, 18 (05) : 693 - 704
  • [10] Gulsen Askin, 2021, Allergol Select, V5, P128, DOI 10.5414/ALX02196E
123